145 related articles for article (PubMed ID: 32219331)
1. PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir.
Yamamoto Y; Kakizaki M; Shimizu T; Carreras J; Chiba T; Chamoto K; Kagawa T; Aoki T; Nakamura N; Ando K; Kotani A
Int Immunol; 2020 Jul; 32(8):519-531. PubMed ID: 32219331
[TBL] [Abstract][Full Text] [Related]
2. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.
Liu J; Zhang E; Ma Z; Wu W; Kosinska A; Zhang X; Möller I; Seiz P; Glebe D; Wang B; Yang D; Lu M; Roggendorf M
PLoS Pathog; 2014 Jan; 10(1):e1003856. PubMed ID: 24391505
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC
Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800
[TBL] [Abstract][Full Text] [Related]
4. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
[TBL] [Abstract][Full Text] [Related]
6. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.
Balsitis S; Gali V; Mason PJ; Chaniewski S; Levine SM; Wichroski MJ; Feulner M; Song Y; Granaldi K; Loy JK; Thompson CM; Lesniak JA; Brockus C; Kishnani N; Menne S; Cockett MI; Iyer R; Mason SW; Tenney DJ
PLoS One; 2018; 13(2):e0190058. PubMed ID: 29444087
[TBL] [Abstract][Full Text] [Related]
8. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
9. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
Reaiche-Miller GY; Thorpe M; Low HC; Qiao Q; Scougall CA; Mason WS; Litwin S; Jilbert AR
Virology; 2013 Nov; 446(1-2):357-64. PubMed ID: 24074600
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response.
Liu L; Hou J; Xu Y; Qin L; Liu W; Zhang H; Li Y; Chen M; Deng M; Zhao B; Hu J; Zheng H; Li C; Meng S
PLoS One; 2020; 15(7):e0228302. PubMed ID: 32628668
[TBL] [Abstract][Full Text] [Related]
11. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
12. Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen.
Li B; Wang Y; Shen F; Wu M; Li Y; Fang Z; Ye J; Wang L; Gao L; Yuan Z; Chen J
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224536
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
14. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
15. The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.
Mason WS; Xu C; Low HC; Saputelli J; Aldrich CE; Scougall C; Grosse A; Colonno R; Litwin S; Jilbert AR
J Virol; 2009 Feb; 83(4):1778-89. PubMed ID: 19073743
[TBL] [Abstract][Full Text] [Related]
16. Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy.
Ma Z; Lu S; Sun D; Bai M; Jiang T; Lin N; Zhou H; Zeng S; Jiang H
Br J Pharmacol; 2019 Sep; 176(17):3236-3249. PubMed ID: 31166004
[TBL] [Abstract][Full Text] [Related]
17. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection.
Xie Z; Chen Y; Zhao S; Yang Z; Yao X; Guo S; Yang C; Fei L; Zeng X; Ni B; Wu Y
Immunol Invest; 2009; 38(7):624-38. PubMed ID: 19811426
[TBL] [Abstract][Full Text] [Related]
19. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
20. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes.
Bohne F; Chmielewski M; Ebert G; Wiegmann K; Kürschner T; Schulze A; Urban S; Krönke M; Abken H; Protzer U
Gastroenterology; 2008 Jan; 134(1):239-47. PubMed ID: 18166356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
